Ivabradine Chanelle Medical

Ivabradine, the active ingredient in Ivabradine Chanelle Medical, is an If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and for heart failure with reduced ejection fraction, helping to lower heart rate without affecting myocardial contractility.

GNH USA supplies Ivabradine Chanelle Medical as a licensed, GDP‑compliant international pharmaceutical supplier, providing the EU‑origin product to hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance.

Ivabradine is used to manage cardiac conditions where heart‑rate reduction improves outcomes.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation by decreasing heart rate. - Patients intolerant to beta‑blockers: offers an alternative mechanism to achieve heart‑rate control.

Common Side Effects: - Bradycardia: unusually slow heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - QT interval prolongation. - Allergic reactions such as rash or angioedema. - Hepatic dysfunction.

Before initiating therapy, consider the following precautions.

- Cardiac monitoring: assess baseline heart rate and rhythm. - Hepatic impairment: avoid or adjust dose in severe liver disease. - Sick sinus syndrome: contraindicated due to risk of excessive bradycardia. - Concomitant bradycardic agents: monitor for additive effects. - Pregnancy and lactation: use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ivabradine plasma levels. - Other bradycardic agents (e.g., beta‑blockers, digoxin): may cause excessive heart‑rate reduction. - Other If channel inhibitors (e.g., ranolazine): additive effect on heart‑rate control.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may raise ivabradine concentrations. - QT‑prolonging drugs: increase risk of cardiac arrhythmias. - Certain antidepressants affecting CYP3A4 (e.g., fluoxetine): require periodic ECG monitoring.